Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SN514-066b in Deep Partial Thickness Dermal Burns
NCT06628037Phase 2Terminated
- Sponsor
- SERDA Therapeutics
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SN514-066b in burn injury, sponsored by SERDA Therapeutics. Started May 2025; status: terminated.
02
Drugs
SN514-066b
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT06628037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06628037.